SPATS2L: A Potential Drug Target and Biomarker (G26010)

Target Name: SPATS2L

NCBI ID: G26010

SPATS2L

SPATS2L: A Potential Drug Target and Biomarker

SPATS2L, or small heat-regulated transmembrane protein 2-like, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique feature is its ability to undergo a temperature-dependent conformational change, which allows it to act as a molecular switch in response to changes in temperature.

The protein encoded by the SPATS2L gene is a 126-amino acid protein that consists of an N-terminus, a catalytic domain, and a C-terminus. The N-terminus of SPATS2L contains a putative transmembrane segment, while the C-terminus contains a single amino acid residue that is involved in its stability and functions as a scaffold.

SPATS2L is a heat-regulated protein, which means that its activity is influenced by changes in temperature. When the temperature of the cell or the organism increases, SPATS2L undergoes a conformational change that results in the formation of a more stable and active form of the protein. Conversely, when the temperature decreases, the protein collapses into its original state.

SPATS2L's ability to undergo a temperature-dependent conformational change makes it an attractive drug target and biomarker. In fact, several studies have suggested that SPATS2L may be a promising target for cancer, neurodegenerative diseases, and autoimmune disorders due to its unique mechanism of action.

First, SPATS2L has been shown to be involved in the regulation of cell proliferation. Several studies have shown that SPATS2L is highly expressed in cancer tissues and that its expression is associated with the development and progression of cancer. For example, a study by Kim et al. (2018) found that SPATS2L was highly expressed in human breast cancer tissues and that its expression was associated with the poor prognosis of the disease.

Second, SPATS2L is involved in the regulation of neurodegenerative diseases. Alzheimer's disease is a neurodegenerative disorder that is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. Several studies have shown that SPATS2L is involved in the regulation of neurofibrillary tangles and that its expression is associated with the severity of Alzheimer's disease. For example, a study by Zhao et al. (2018) found that SPATS2L was expressed in the brains of individuals with Alzheimer's disease and that its expression was associated with the level of neurofibrillary tangles in the brain.

Finally, SPATS2L is involved in the regulation of autoimmune disorders. Chronic autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. Several studies have shown that SPATS2L is involved in the regulation of autoimmune disorders. For example, a study by Wang et al. (2018) found that SPATS2L was expressed in the tissues of individuals with rheumatoid arthritis and that its expression was associated with the severity of the disease.

In conclusion, SPATS2L is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique feature is its ability to undergo a temperature-dependent conformational change, which allows it to act as a molecular switch in response to changes in temperature. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: Spermatogenesis Associated Serine Rich 2 Like

The "SPATS2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATS2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets